$5.48
-5.03% (Daily)
Market Cap
$1.88B
Revenue
$26.75M
Rank by MCap
#1392
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. David T. Hung M.D.
Headquarters
New York, NY
Employees
291
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors...
Loading chart…